This phase I/II trial studies the side effects and best dose of lorlatinib when given together with ramucirumab and to see how well it works in treating patients with non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cancer has a change (fusion) involving the ALK gene (called ALK-rearranged). A fusion gene is made in the body when parts of two different genes join together. Lorlatinib is routinely used to treat ALK-rearranged NSCLC and works to prevent cancer spread by interfering with the growth of cancer cells, which are eventually destroyed by the body. Ramucirumab is a type of drug called a monoclonal antibody. Monoclonal antibodies are similar to the antibodies your body makes to fight infections caused by bacteria or viruses. Ramucirumab binds to a molecule called VEGF Receptor 2 (VGFR-2) that promotes the growth of cancer cells. Binding to this receptor may slow or stop the growth and spread of cancer. Giving lorlatinib in combination with ramucirumab may work better in treating patients with advanced ALK-rearranged NSCLC.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06007937.
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) and safety of combination of lorlatinib and ramucirumab in patients with advanced ALK-rearranged lung cancers. (Phase 1: safety run in)
II. To determine the 12-month progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with advanced lorlatinib ALK-rearranged lung cancers treated with lorlatinib and ramucirumab in the TKI-naive and the tyrosine kinase inhibitors (TKI)-treated setting using two patient cohorts:
IIa. Cohort 1: patients who have not received a prior ALK inhibitor;
IIb. Cohort 2: patients with disease progression on a second-generation ALK. (Phase 2)
SECONDARY OBJECTIVES:
I. Overall response rate (ORR)
II. Overall survival (OS)
III. Intracranial PFS
IV. Intracranial ORR
V. To further characterize the tolerability of the combination
CORRELATIVE/EXPLORATORY OBJECTIVES:
I. To identify genomic markers associated with response to lorlatinib and ramucirumab treatment, using next-generation sequencing (NGS) of pre-treatment archival samples.
II. To determine whether early circulating-tumor deoxyribonucleic acid (ctDNA) clearance at 6 and 12 weeks is associated with prolonged PFS in patients treated with the combination.
OUTLINE: This is a phase I, dose-escalation study of lorlatinib followed by a phase II study.
Patients receive lorlatinib orally (PO) once daily (QD) and ramucirumab intravenously (IV) over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computerized tomography (CT) and magnetic resonance imaging (MRI) and blood sample collection throughout the trial.
After completion of study treatment, patients are followed up at 30 days then up to 1 year.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorGregory J. Riely